FDA briefing documents note Xarelto bleeding

FDA briefing documents released in advance of Thursday's Cardiovascular and Renal Drugs Advisory Committee meeting on Xarelto rivaroxaban from Johnson & Johnson

Read the full 220 word article

User Sign In